Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romosozumab vs Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta
NCT05972551Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- Apr 2024
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies
- Countries
- 18
01
Overview
Phase 3, randomised, open-label trial in osteogenesis imperfecta (OI) comparing Romosozumab with Standard of Care Bisphosphonate (2 arms). Primary endpoints: Number of Clinical Fractures at 12 months, Number of Any Fractures at 12 months and 1 more. Started Apr 2024; status: active, not recruiting.
02
Drugs
romosozumab
03
Conditions
osteogenesis imperfecta (OI)
Beyond the preview
Go deeper on NCT05972551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05972551.